Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AEROSEB-DEX vs BREO ELLIPTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Ophthalmic corticosteroid-responsive inflammatory conditions with concurrent bacterial infection or risk of infection,Blepharitis,Conjunctivitis,Keratitis,Iritis,Cyclitis
Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema,Maintenance treatment of asthma in patients aged 18 years and older
2 puffs (100 mcg each) intranasally twice daily
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
Terminal elimination half-life is 12-15 hours in adults with normal renal function; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Dexamethasone is metabolized primarily in the liver via CYP3A4; topical antibiotics (neomycin, polymyxin B) are minimally absorbed and not significantly metabolized.
Fluticasone furoate: primarily metabolized by CYP3A4; Vilanterol: primarily metabolized by CYP3A4.
Renal elimination of unchanged drug accounts for 30-40% of the dose; fecal/biliary elimination is 50-60% as metabolites. Less than 10% is excreted unchanged in feces.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein.
Fluticasone furoate: >99.8% (primarily albumin). Vilanterol: approximately 94% (albumin and alpha-1-acid glycoprotein).
Vd is 3-4 L/kg, indicating extensive tissue distribution with accumulation in liver and kidneys.
Fluticasone furoate: approximately 4.5 L/kg (extensive tissue distribution). Vilanterol: approximately 165 L (large Vd, extensive distribution).
Oral: 40-50% due to first-pass metabolism; Topical: 5-10% systemically; IV: 100%.
Inhaled: Fluticasone furoate absolute bioavailability approximately 15% (lung deposition). Vilanterol absolute bioavailability approximately 27% (lung deposition). Oral bioavailability is negligible for both (<2% for fluticasone furoate, <5% for vilanterol).
No adjustment required for any GFR level
No dosage adjustment required for renal impairment. However, use with caution in severe renal impairment due to potential for increased systemic exposure.
Child-Pugh Class A: no adjustment; Child-Pugh Class B/C: no data available; use with caution
Child-Pugh Class A and B: No dosage adjustment recommended. Child-Pugh Class C: Contraindicated.
Children 6-11 years: 1 puff (50 mcg) per nostril twice daily; Children ≥12 years: same as adult
Indicated for children aged 5 years and older with asthma. For ages 5-11: one inhalation of 100 mcg/25 mcg once daily. For ages 12 and older: same as adult dosing.
No specific dose adjustment; monitor for adrenal suppression and osteoporosis risk with prolonged use
No dose adjustment required for elderly patients. Use with caution due to increased risk of comorbidities and adverse effects.
Prolonged use may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Use only as additional therapy for patients not adequately controlled on a long-term asthma control medication or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
Prolonged use may lead to ocular hypertension/glaucoma,Posterior subcapsular cataract formation,Delayed wound healing,Secondary ocular infections (including fungal infections),Corneal/scleral thinning and perforation,Systemic absorption with prolonged use (especially in children),Avoid use in patients with known hypersensitivity to any component
Increased risk of asthma-related death when used as monotherapy for asthma without inhaled corticosteroid,Candida infections of the mouth and pharynx,Pneumonia in patients with COPD,Adrenal insufficiency,Hypercorticism and adrenal suppression,Paradoxical bronchospasm,Hypersensitivity reactions including anaphylaxis,Cardiovascular effects like increased blood pressure and heart rate,Eosinophilic conditions,Reduced bone mineral density,Glaucoma and cataracts
Epithelial herpes simplex keratitis (dendritic keratitis),Vaccinia, varicella, and other viral infections of the cornea and conjunctiva,Mycobacterial infections of the eye,Fungal diseases of ocular structures,Hypersensitivity to any component of the formulation
Status asthmaticus or acute episodes of COPD requiring intensive therapy,Primary treatment of acute asthma exacerbation,Severe hypersensitivity to milk proteins or any ingredient
No specific food interactions. Avoid grapefruit juice as it may increase systemic exposure to ciclesonide via CYP3A4 inhibition.
No specific food interactions reported. However, grapefruit juice may increase systemic exposure to fluticasone furoate via CYP3A4 inhibition; although clinical significance is low, avoid excessive grapefruit consumption. No dietary restrictions necessary.
Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm due to pharmacological effects; use only if clearly needed.
Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at high systemic exposures. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Excreted in human milk in unknown amounts; M/P ratio not established. Caution advised due to potential for serious adverse reactions in nursing infants; discontinue drug or nursing depending on importance to mother.
No data on drug excretion in human milk; M/P ratio unknown. Corticosteroids and LABAs are expected to be present in low concentrations. Caution if breastfeeding, especially in preterm infants. Consider alternative therapies.
No established dose adjustments in pregnancy; pharmacokinetics may be altered due to increased plasma volume and metabolism. Use lowest effective dose; individualize therapy based on clinical response.
No specific dose adjustments required due to pregnancy-induced pharmacokinetic changes, but use lowest effective dose to maintain asthma control due to potential fetal risk.
AEROSEB-DEX is a fixed-dose combination of an inhaled corticosteroid (ciclesonide) and a long-acting beta-agonist (formoterol). Use as maintenance therapy for asthma, not for acute bronchospasm. Rinse mouth after inhalation to prevent oral candidiasis. Monitor for adrenal suppression with prolonged use. Dose formoterol component at low to moderate doses to minimize risk of asthma-related death.
Breo Ellipta (fluticasone furoate/vilanterol) is an ICS/LABA combination indicated for maintenance treatment of COPD and asthma. It is not for acute bronchospasm. The ELLIPTA inhaler is a once-daily, dry powder inhaler; each actuation delivers a fixed dose. Rinse mouth with water after use without swallowing to reduce oral candidiasis. Monitor for pneumonia in COPD patients. In asthma, it is not indicated for patients under 18 years; for COPD, use only in patients with a history of exacerbations. Do not discontinue abruptly.
Use regularly as prescribed, not for sudden breathing problems.,Rinse mouth with water after each use to prevent thrush.,Do not stop suddenly; taper under doctor guidance.,Seek emergency if rescue inhaler not effective.,Report worsening asthma, chest pain, or signs of steroid excess.
Use exactly as prescribed; it is not a rescue inhaler for sudden breathing problems.,Rinse mouth with water after each dose without swallowing to prevent oral thrush.,Do not stop taking this medication without consulting your doctor; stopping can worsen breathing.,Tell your doctor if you have any signs of infection, pneumonia, or worsening breathing.,Store the inhaler at room temperature away from moisture and heat; keep it closed when not in use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AEROSEB-DEX vs BREO ELLIPTA, answered by our medical review team.
AEROSEB-DEX is a Topical Corticosteroid that works by The combination product contains a corticosteroid (dexamethasone) which suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and a topical antibiotic (usually neomycin or polymyxin B) which inhibits bacterial protein synthesis or disrupts bacterial cell membranes.. BREO ELLIPTA is a Corticosteroid/Beta-2 Agonist Combination that works by Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AEROSEB-DEX and BREO ELLIPTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AEROSEB-DEX is: 2 puffs (100 mcg each) intranasally twice daily. The standard adult dose of BREO ELLIPTA is: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AEROSEB-DEX and BREO ELLIPTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AEROSEB-DEX is classified as Category C. Pregnancy Category C. First trimester: potential for teratogenicity based on animal studies; avoid unless benefit outweighs risk. Second/third trimester: drug may cause fetal harm . BREO ELLIPTA is classified as Category C. Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.